HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.

AbstractBACKGROUND:
Pegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD in patients treated during routine clinical practice.
METHODS:
Eligible patients had metastatic breast cancer and were treated with PLD according to the dose and schedule determined by their physician as part of routine practice. The primary objectives were to analyze the efficacy and toxicity of PLD therapy.
RESULTS:
125 patients were assessable. Median age was 62 years, 78% had performance status 0-1, and 60% had estrogen-receptor-positive disease. PLD treatment was second- or third-line in 69% of patients. Prior anthracyclines (adjuvant or metastatic) had been used in 56% of patients. The majority of patients (79%) received PLD every 4 weeks at a median dose of 40 mg/m2. Overall response rate was 43% in all patients and 34% in those previously treated with anthracyclines. The most common grade 3/4 adverse events were skin toxicity/hand-foot syndrome (6%), and leukopenia (3%).
CONCLUSIONS:
This observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials.
AuthorsJens Huober, Werner Fett, Arnd Nusch, Michael Neise, Marcus Schmidt, Arthur Wischnik, Steffen Gerhardt, Thomas Goehler, Hans-Joachim Lück, Andreas Rost
JournalBMC cancer (BMC Cancer) Vol. 10 Pg. 2 (Jan 05 2010) ISSN: 1471-2407 [Electronic] England
PMID20047698 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Antibiotics, Antineoplastic
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Doxorubicin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic (adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy, pathology)
  • Disease-Free Survival
  • Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Observation
  • Polyethylene Glycols (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: